Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview

Longboard Pharmaceuticals

08/11/2024 15:53

* Longboard Pharmaceuticals Inc  LBPH.OQ   LBPH.O  is
expected
to show no change in quarterly revenue when it reports  results 
for the period ending December 31 2024
    * 
    * ​LSEG's mean analyst estimate for Longboard
Pharmaceuticals Inc
is for a loss of 62 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Longboard
Pharmaceuticals Inc is $60.00​, above​ its last closing price
of $59.78. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.58       -0.58      -0.63     Missed  -8.9
 Jan. 1 0001   -0.45       -0.44      -0.56     Missed  -27.1
 Mar. 31 2024  -0.49       -0.49      -0.42     Beat    13.6​
 Dec. 31 2023  -0.60       -0.60      -0.62     Missed  -3.8
 ​​Sep.        -0.70       -0.70      -0.55     Beat    21.9
 30 2023                                                
 Jun. 30 2023  -0.58                  -0.65             -9.1​
 Jan. 1 0001   -0.57       -0.57      -0.56     Beat    2.5
 Dec. 31 2022  -0.70       -0.69      -0.66     Beat    5
 This summary was machine generated November 8 at 15:52 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)